BiotechTube
Home/Pipeline/InFUSE Platform Candidate(s)

InFUSE Platform Candidate(s)

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication
Oncology (unspecified)
Phase
Pre-clinical
Status
Active
Company
Fusix Biotech

About Fusix Biotech

Fusix Biotech is a private, preclinical-stage biotech developing novel oncolytic virus therapies for cancer. Its core asset is the InFUSE platform, which aims to combine potent tumor cell killing via fusogenic cell death with a favorable safety profile and systemic intravenous delivery. The company is led by its four scientific founders, is supported by academic partnerships and pre-seed grants, and is currently focused on advancing its platform through preclinical proof-of-concept and manufacturing setup.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a